Literature DB >> 18299472

Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.

Ying Y Liu1, Hans Morreau, Job Kievit, Johannes A Romijn, Nancy Carrasco, Johannes W Smit.   

Abstract

OBJECTIVES: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology. This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms. Our study differed from earlier ones with regard to the identification of optimal semiquantitative cut-off levels using receiver operator curve (ROC) analysis and hierarchical cluster analysis.
METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)). Antibody staining was scored semiquantitatively based on the ROC analyses and with hierarchical cluster analysis.
RESULTS: In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1, and iNIS in malignant thyroid lesions. Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions. A panel of Gal-3, FN-1, and iNIS, identified by hierarchical cluster analysis, had a 98% accuracy to differentiate between FA and malignant thyroid lesions. In addition, HBME-1 was found to be useful in the differentiation between FA and FVPTC (accuracy 88%).
CONCLUSION: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy (98%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299472     DOI: 10.1530/EJE-07-0492

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

1.  Diagnostic utility of immunohistochemical panel in various thyroid pathologies.

Authors:  Arturs Ozolins; Zenons Narbuts; Ilze Strumfa; Guna Volanska; Janis Gardovskis
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 2.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

3.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

Review 4.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 5.  Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Leo Guidobaldi; Enrico Saggiorato; Giuseppe Nigri; Anna Crescenzi; Francesco Romanelli; Fabio Orlandi; Stefano Valabrega; Ramin Sadeghi; Luca Giovanella
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

6.  High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis.

Authors:  Júlia Németh; Zsuzsanna Németh; Péter Tátrai; Ilona Péter; Aron Somorácz; Attila Marcell Szász; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2009-07-05       Impact factor: 3.201

7.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms.

Authors:  B S Sumana; Sampangiram Shashidhar; A S Shivarudrappa
Journal:  J Clin Diagn Res       Date:  2015-11-01

Review 8.  Advanced thyroid cancers: new era of treatment.

Authors:  Amrallah A Mohammed; Ayman El-Shentenawy
Journal:  Med Oncol       Date:  2014-06-08       Impact factor: 3.064

9.  Galectins as cancer biomarkers.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Avraham Raz
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

Review 10.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.